Fnx Performance products are intended strictly for qualified in vitro laboratory research. For Research Use Only. Not for human or animal consumption. Not for compounding or therapeutic application.
Explore mechanism data, evidence tiers, safety, and regulatory context for every compound in the Fnx catalog. Each peptide has its own research profile, filter by category or follow a tag from any product page.
FDA approved with randomized controlled trials behind the approved use.
A large or maturing human RCT base, but not (yet) FDA approved for this use.
Registered and used abroad (e.g. Russia) on modest, mostly single institution trials.
A plausible mechanism, but human efficacy for the marketed use is unproven.
Animal/in vitro data and anecdote only, little to no human evidence and real safety unknowns.
A short chain tripeptide bioregulator (Glu-Asp-Arg) from the Khavinson program, studied for neuroprotection and a proposed, but under validated, direct gene promoter binding mechanism.
A synthetic heptapeptide analog of ACTH(4-10) with CNS activity but no corticotropic effect, used in Russia as a nootropic/neuroprotective agent.
A synthetic heptapeptide analog of tuftsin studied as a non sedating anxiolytic, modulating GABA/serotonin systems and raising BDNF without dependence in studied models.
An angiotensin IV analog reported in preclinical models to be a potent procognitive/synaptogenic compound acting via HGF/c-Met signaling.